These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

333 related articles for article (PubMed ID: 21881697)

  • 41. Effects of telmisartan, ramipril, and their combination on left ventricular hypertrophy in individuals at high vascular risk in the Ongoing Telmisartan Alone and in Combination With Ramipril Global End Point Trial and the Telmisartan Randomized Assessment Study in ACE Intolerant Subjects With Cardiovascular Disease.
    Verdecchia P; Sleight P; Mancia G; Fagard R; Trimarco B; Schmieder RE; Kim JH; Jennings G; Jansky P; Chen JH; Liu L; Gao P; Probstfield J; Teo K; Yusuf S;
    Circulation; 2009 Oct; 120(14):1380-9. PubMed ID: 19770395
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Cardiovascular and renal outcomes with telmisartan, ramipril, or both in people at high renal risk: results from the ONTARGET and TRANSCEND studies.
    Tobe SW; Clase CM; Gao P; McQueen M; Grosshennig A; Wang X; Teo KK; Yusuf S; Mann JF;
    Circulation; 2011 Mar; 123(10):1098-107. PubMed ID: 21357827
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Hypertension therapy for type 2 diabetics].
    Bönner G
    MMW Fortschr Med; 2007 Jun; 149(23):45, 47-8. PubMed ID: 18062579
    [No Abstract]   [Full Text] [Related]  

  • 44. ARBs and ACEis together in the treatment of hypertension and its complications? current practical recommendations.
    Ruilope LM; Segura J
    Expert Opin Pharmacother; 2010 Nov; 11(16):2619-23. PubMed ID: 20977398
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Telmisartan, ramipril, or both in high-risk Chinese patients: analysis of ONTARGET China data.
    Yu LT; Zhu J; Tan HQ; Wang GG; Teo KK; Liu LS
    Chin Med J (Engl); 2011 Jun; 124(12):1763-8. PubMed ID: 21740829
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Positive added effect of telmisartan. New therapy alternative for a large collection of cardiovascular risk patients].
    MMW Fortschr Med; 2010 Feb; 152(8):48-9. PubMed ID: 20358766
    [No Abstract]   [Full Text] [Related]  

  • 47. ONTARGET: questions asked, questions answered.
    Weber MA
    J Clin Hypertens (Greenwich); 2008 Jun; 10(6):427-30. PubMed ID: 18550931
    [No Abstract]   [Full Text] [Related]  

  • 48. [Vascular patient with high infarction risk. Does the AT-1 blocker protect as well as an ACE inhibitor?].
    MMW Fortschr Med; 2003 Dec; 145(51-52):39. PubMed ID: 14974331
    [No Abstract]   [Full Text] [Related]  

  • 49. Importance of a fixed combination of telmisartan and amlodipine for the treatment of hypertension.
    Ahrens K; Bramlage P
    Drugs Today (Barc); 2010 May; 46(5):339-50. PubMed ID: 20517535
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Comparative review of the blood pressure-lowering and cardiovascular benefits of telmisartan and perindopril.
    Wang JG; Pimenta E; Chwallek F
    Vasc Health Risk Manag; 2014; 10():189-200. PubMed ID: 24741317
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Inhibition of the renin-angiotensin-aldosterone system: is there room for dual blockade in the cardiorenal continuum?
    Volpe M; Danser AH; Menard J; Waeber B; Mueller DN; Maggioni AP; Ruilope LM
    J Hypertens; 2012 Apr; 30(4):647-54. PubMed ID: 22278139
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Telmisartan, ramipril, or both in patients at high risk for vascular events. Results of the ONTARGET trial].
    Liakishev AA
    Kardiologiia; 2008; 48(5):72. PubMed ID: 18537808
    [No Abstract]   [Full Text] [Related]  

  • 53. Comparative role of angiotensin receptor blockers versus other agents in the management of hypertension, cardiovascular disease and nephropathy.
    Tempelhof MW
    South Med J; 2009 Dec; 102(12):1201-2. PubMed ID: 20016423
    [No Abstract]   [Full Text] [Related]  

  • 54. Recent changes in the landscape of combination RAS blockade.
    Epstein BJ; Smith SM; Choksi R
    Expert Rev Cardiovasc Ther; 2009 Nov; 7(11):1373-84. PubMed ID: 19900020
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Blood pressure targets recommended by guidelines and incidence of cardiovascular and renal events in the Ongoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial (ONTARGET).
    Mancia G; Schumacher H; Redon J; Verdecchia P; Schmieder R; Jennings G; Yusoff K; Ryden L; Liu GL; Teo K; Sleight P; Yusuf S
    Circulation; 2011 Oct; 124(16):1727-36. PubMed ID: 21947289
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
    Weir MR
    Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Angiotensin II type 1 receptor blockade: high hopes sent back to reality?
    Grothusen A; Divchev D; Luchtefeld M; Schieffer B
    Minerva Cardioangiol; 2009 Dec; 57(6):773-85. PubMed ID: 19942847
    [TBL] [Abstract][Full Text] [Related]  

  • 58. From evidence to rationale: cardiovascular protection by angiotensin II receptor blockers compared with angiotensin-converting enzyme inhibitors.
    Böhm M; Baumhäkel M; Mahfoud F; Werner C
    Cardiology; 2010; 117(3):163-73. PubMed ID: 21051889
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Telmisartan (micardis) -- an antagonist of angiotensin 2 of type 1 receptors: another antihypertensive drug or something greater?].
    Chazova IE
    Ter Arkh; 2003; 75(6):89-91. PubMed ID: 12920969
    [No Abstract]   [Full Text] [Related]  

  • 60. [Treatment of hypertension. Effectiveness of sartans is far from exhausted].
    MMW Fortschr Med; 2007 Dec; 149(51-52):54-5. PubMed ID: 18246832
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.